Private Wealth Partners LLC held its stake in Eli Lilly and Co. (NYSE:LLY) during the second quarter, Holdings Channel reports. The institutional investor owned 9,175 shares of the company’s stock at the end of the second quarter. Private Wealth Partners LLC’s holdings in Eli Lilly and were worth $723,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Renaissance Technologies LLC increased its stake in Eli Lilly and by 565.1% in the first quarter. Renaissance Technologies LLC now owns 2,213,605 shares of the company’s stock worth $159,402,000 after buying an additional 1,880,800 shares in the last quarter. Beutel Goodman & Co Ltd. purchased a new stake in Eli Lilly and during the second quarter worth $104,345,000. Bank of Montreal Can purchased a new stake in Eli Lilly and during the second quarter worth $86,545,000. Franklin Resources Inc. increased its stake in Eli Lilly and by 3.6% in the first quarter. Franklin Resources Inc. now owns 27,744,978 shares of the company’s stock worth $1,997,920,000 after buying an additional 961,204 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. purchased a new stake in Eli Lilly and during the first quarter worth $61,280,000. 74.96% of the stock is owned by institutional investors.
Eli Lilly and Co. (NYSE:LLY) traded up 0.79% during trading on Wednesday, hitting $81.75. The company’s stock had a trading volume of 3,560,429 shares. Eli Lilly and Co. has a 12 month low of $67.88 and a 12 month high of $88.16. The firm has a 50 day moving average of $79.34 and a 200 day moving average of $77.38. The firm has a market cap of $86.47 billion, a P/E ratio of 35.24 and a beta of 0.17.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.86. The company had revenue of $5.40 billion for the quarter, compared to analysts’ expectations of $5.14 billion. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. Eli Lilly and’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period last year, the firm posted $0.90 EPS. Equities research analysts predict that Eli Lilly and Co. will post $3.59 earnings per share for the current year.
A number of equities research analysts have recently weighed in on LLY shares. Jefferies Group lifted their target price on Eli Lilly and from $100.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, July 14th. Goldman Sachs Group Inc. raised Eli Lilly and from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $89.00 to $95.00 in a report on Tuesday, September 27th. Zacks Investment Research downgraded Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Thursday, August 4th. Argus boosted their price target on Eli Lilly and from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, August 2nd. Finally, JPMorgan Chase & Co. raised Eli Lilly and from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $92.00 to $95.00 in a research note on Thursday, September 8th. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $97.16.
In related news, major shareholder Lilly Endowment Inc sold 240,000 shares of the firm’s stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $82.87, for a total transaction of $19,888,800.00. Following the transaction, the insider now directly owns 126,020,570 shares of the company’s stock, valued at approximately $10,443,324,635.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jackson P. Tai acquired 2,560 shares of the firm’s stock in a transaction that occurred on Friday, August 12th. The shares were purchased at an average cost of $80.42 per share, for a total transaction of $205,875.20. Following the completion of the acquisition, the director now owns 42,110 shares in the company, valued at approximately $3,386,486.20. The disclosure for this purchase can be found here. Corporate insiders own 0.20% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co. (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.